Search Result

Results for "

pulmonary artery

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Acyltransferase (2) Adrenergic Receptor (4) Akt (1) Apoptosis (1) Arp2/3 Complex (1) Autophagy (1) Bcl-2 Family (1) Calcium Channel (1) Caspase (1) CaSR (1) Collagen (1) COX (2) Cytochrome P450 (1) DAGL (2) Drug Metabolite (1) Endogenous Metabolite (1) Endothelin Receptor (4) G Protein-coupled Receptor Kinase (GRK) (1) GABA Receptor (1) Guanylate Cyclase (1) Interleukin Related (1) LPL Receptor (1) Lysyl Oxidase (1) mAChR (2) MetAP (1) mGluR (1) Monoamine Oxidase (1) mTOR (1) NADPH Oxidase (2) Neurokinin Receptor (1) NF-κB (1) NO Synthase (1) Phospholipase (2) PI3K (1) PKG (1) Potassium Channel (1) Pregnane X Receptor (PXR) (1) Prostaglandin Receptor (7) Reference Standards (4) ROCK (1) SARS-CoV (1) Sodium Channel (1) Thrombopoietin Receptor (1) TRP Channel (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (28) Endocrinology (4) Infection (1) Inflammation/Immunology (4) Metabolic Disease (5) Neurological Disease (8)

By Targets:

5-HT Receptor (3)

Acyltransferase (2)

Adrenergic Receptor (4)

Akt (1)

Apoptosis (1)

Arp2/3 Complex (1)

Autophagy (1)

Bcl-2 Family (1)

Calcium Channel (1)

Caspase (1)

CaSR (1)

Collagen (1)

COX (2)

Cytochrome P450 (1)

DAGL (2)

Drug Metabolite (1)

Endogenous Metabolite (1)

Endothelin Receptor (4)

G Protein-coupled Receptor Kinase (GRK) (1)

GABA Receptor (1)

Guanylate Cyclase (1)

Interleukin Related (1)

LPL Receptor (1)

Lysyl Oxidase (1)

mAChR (2)

MetAP (1)

mGluR (1)

Monoamine Oxidase (1)

mTOR (1)

NADPH Oxidase (2)

Neurokinin Receptor (1)

NF-κB (1)

NO Synthase (1)

Phospholipase (2)

PI3K (1)

PKG (1)

Potassium Channel (1)

Pregnane X Receptor (PXR) (1)

Prostaglandin Receptor (7)

Reference Standards (4)

ROCK (1)

SARS-CoV (1)

Sodium Channel (1)

Thrombopoietin Receptor (1)

TRP Channel (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (28)

Endocrinology (4)

Infection (1)

Inflammation/Immunology (4)

Metabolic Disease (5)

Neurological Disease (8)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12378

BQ-123 3 Publications Verification	Endothelin Receptor	Cardiovascular Disease
BQ-123 is a potent and selective endothelin A (ETA) receptor antagonist with an IC₅₀ of 7.3 nM and a K_i of 25 nM. BQ-123 inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells and lowers blood pressure in different rat models of hypertension .

HY-101369

BW-723C86 1 Publications Verification	5-HT Receptor	Cardiovascular Disease Neurological Disease
BW-723C86 is an orally active and a selective 5-HT_2B receptor agonist. BW-723C86 exhibits anxiolytic-like actions. BW-723C86 also causes hyperphagia and reduced grooming in rats. BW-723C86 dilates pulmonary arteries and inhibits liquid meal-induced gastric accommodation .

HY-107416

RHC 80267 U-57908	DAGL Acyltransferase mAChR COX Phospholipase	Neurological Disease Metabolic Disease
RHC 80267 (U-57908) is a potent and selective inhibitor of diacylglycerol lipase (DAGL) (with IC₅₀ of 4 μM in canine platelets). RHC-80267 inhibits cholinesterase activity with an IC₅₀ of 4 μM, thereby enhancing the relaxation evoked by acetylcholine. RHC 80267 also inhibits COX and the hydrolysis of phosphatidylcholine (PC) .

HY-P2031

Phallacidin	Arp2/3 Complex	Others
Phallacidin is a natural bicyclic heptapeptide derived from the poisonous mushroom Amanita phalloides. Phallacidin binds to filamentous actin specifically with high affinity, with a K_d of 20 nM. After binding to F-actin, Phallacidin strongly inhibits its depolymerization, stabilizes microfilament structures, and prevents their disruption by drugs such as cytochalasins. When conjugated with a fluorophore, Phallacidin serves as a specific fluorescent probe for F-actin, which is used to clearly visualize the distribution of actin in the cytoskeleton (e.g., stress fibers, cortical peripheral bands) under fluorescence microscopy .

HY-11095

NPS 2390	mGluR CaSR PI3K Akt mTOR Autophagy Apoptosis Bcl-2 Family Caspase	Cardiovascular Disease Neurological Disease
NPS 2390 is an allosteric antagonist of calcium-sensing receptor (CaSR) and mGluR1/5. NPS 2390 inhibits the PI3K/Akt/mTOR signaling pathway, reduces hypoxia-induced intracellular calcium elevation, decreases the expression of autophagy (autophagy) proteins, regulates the expression of phenotypic marker proteins, and inhibits the proliferation of pulmonary artery smooth muscle cells. NPS 2390 attenuates the endogenous apoptosis (apoptosis) pathway, increases the expression level of Bcl-2, downregulates the expression levels of Bax, cytochrome c and caspase-3, alleviates cerebral edema and improves neurological function in rat models. NPS 2390 can be used in studies related to hypoxic pulmonary hypertension, traumatic brain injury, stroke and pain .

HY-134216

MAHMA NONOate 1 Publications Verification	Endogenous Metabolite NO Synthase	Cardiovascular Disease
MAHMA NONOate is a NO donor. MAHMA NONOate effectively inhibits platelet aggregation induced by either collagen or ADP .

HY-N6066

Praeruptorin E	Calcium Channel NF-κB Pregnane X Receptor (PXR) Cytochrome P450 Interleukin Related	Cardiovascular Disease Inflammation/Immunology
Praeruptorin E is an orally active pyranocoumarin compound. Praeruptorin E can be isolated from the dried roots of Peucedanum praeruptorum Dunn. Praeruptorin E reduces the expression of NF-κB. Praeruptorin E upregulates the expression of PXR and CYP3A4. Praeruptorin E inhibits Th2 cytokines, TNF-α, IL6, MPO, and blocks the Ca ²⁺ slow channel. Praeruptorin E promotes pulmonary tissue repair and relaxes porcine coronary artery strips. Praeruptorin E protects mice from lipopolysaccharide- and hydrochloric acid-induced acute lung injury. Praeruptorin E can be used in studies related to asthma and acute lung injury .

HY-108464A

Phenamil methanesulfonate	Sodium Channel TRP Channel	Metabolic Disease Inflammation/Immunology
Phenamil methanesulfonate, an analog of Amiloride (HY-B0285), is a more potent and less reversible epithelial sodium channel (ENaC) blocker with an IC₅₀ of 400 nM . Phenamil methanesulfonate is also a competive inhibitor of TRPP3 and inhibits TRPP3-mediated Ca ²⁺ transport with an IC₅₀ of 140 nM in a Ca ²⁺ uptake assay . Phenamil methanesulfonate is an intriguing small molecule to promote bone repair by strongly activating BMP signaling pathway . Phenamil methanesulfonate is used for the research of cystic fibrosis lung disease .

HY-B1298

Methoxamine hydrochloride	Adrenergic Receptor	Neurological Disease Endocrinology
Methoxamine hydrochloride is a selective alpha1-adrenergic receptor agonist. Methoxamine hydrochloride causes vasoconstriction and increased peripheral vascular resistance . Methoxamine hydrochloride significantly increased the overflow of ATP, ADP and AMP, but not adenosine, by a prazosin-sensitive mechanism in the rabbit pulmonary artery .

HY-P1435

NoxA1ds	NADPH Oxidase	Cardiovascular Disease Cancer
NoxA1ds is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds inhibits NOX1-derived O ^2- production in HT-29 human colon cancer cells. NoxA1ds attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds can be used in the study of hypertension, atherosclerosis and tumors .

HY-B0813

Treprostinil diethanolamine 1 Publications Verification UT-15C	Prostaglandin Receptor	Endocrinology
Treprostinil (UT-15C) diethanolamine is a potent EP2, DP1 and IP agonist with K_i values of 3.6, 4.4, 32.1, 212, 826, 2505 and 4680 nM for EP2, DP1, IP, EP1, EP4, EP3 and FP, respectively. Treprostinil (UT-15C) diethanolamine increases upregulation of cAMP toward maintaining homeostasis within the vasculature. Treprostinil (UT-15C) diethanolamine can result in vasodilatation of human pulmonary arteries .

HY-103653

CKD-731	MetAP	Cardiovascular Disease Cancer
CKD-731 is a Fumagillin (HY-B0751) analogue. CKD-731 inhibits the proliferation of calf pulmonary artery endothelial cells (CPAE), lymphoma EL-4 cells and murine leukemia P388D1 cells. CKD-731 exerts the effect of inhibiting MetAP-2 activity and blocking angiogenesis. CKD-731 can be used for the research of anti-angiogenesis-related cancer .

HY-101393A

CGP 12177 hydrochloride (±)-CGP 12177 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease
CGP 12177 ((±)-CGP 12177) hydrochloride is a β-Adrenergic receptor (β-AR) ligand. CGP 12177 hydrochloride is a β₃-AR (K_i = 88 nM) agonist with β₁/β₂-AR (K_i = 0.9 nM for β₁; K_i = 4 nM for β₂) antagonist action. CGP 12177 hydrochloride exhibits partial agonist properties for α₁-AR in rat pulmonary artery. CGP 12177 hydrochloride regulates the expression of ucp and leptin genes in NMRI mice adipose tissues. CGP 12177 hydrochloride can be used for cardiovascular and metabolic disease research ^[1][2][3][4].

HY-B1298A

Methoxamine	Adrenergic Receptor	Cardiovascular Disease
Methoxamine is a selective alpha1-adrenergic receptor agonist. Methoxamine causes vasoconstriction and increased peripheral vascular resistance . Methoxamine hydrochloride significantly increased the overflow of ATP, ADP and AMP, but not adenosine, by a prazosin-sensitive mechanism in the rabbit pulmonary artery .

HY-P1016B

BQ-3020 ammonium	Endothelin Receptor	Cardiovascular Disease
BQ-3020 ammonium is a selective endothelin receptor (ET_B receptor) agonist. BQ-3020 ammonium inhibits [ ¹²⁵I] ET-1 binding to ET_B receptors, with an IC₅₀ value of 0.2 nM. BQ-3020 ammonium elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 ammonium makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research . .

HY-P1016

BQ-3020	Endothelin Receptor	Cardiovascular Disease
BQ-3020 is a selective endothelin receptor (ET_B receptor) agonist that displaces [ ¹²⁵I] ET-1 binding to ET_B receptors, with an IC₅₀ value of 0.2 nM. BQ-3020 elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research ¹ ².

HY-177948

GRK2 degrader-1	G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
GRK2 degrader-1 (compound 1) is a potent and orally active GRK2 degrader. GRK2 degrader-1 degrades GRK2 via the ubiquitin-proteasome pathway. GRK2 degrader-1 inhibits right ventricular remodeling and elevation of pulmonary artery pressure in a pulmonary artery hypertension (PAH) mouse model. GRK2 degrader-1 can be used for PAH research .

HY-101393

CGP 12177 (±)-CGP 12177	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease
CGP 12177 ((±)-CGP 12177) is a β-Adrenergic receptor (β-AR) ligand. CGP 12177 is a β₃-AR (K_i = 88 nM) agonist with β₁/β₂-AR (K_i = 0.9 nM for β₁; K_i = 4 nM for β₂) antagonist action. CGP 12177 exhibits partial agonist properties for α₁-AR in rat pulmonary artery. CGP 12177 regulates the expression of ucp and leptin genes in NMRI mice adipose tissues. CGP 12177 can be used for cardiovascular and metabolic disease research .

HY-121020

Arcapillin	SARS-CoV	Infection Others Inflammation/Immunology
Arcapillin is a flavonoid that can be isolated from Artemisia capillaris Thunb. Arcapillin induces dose-dependent relaxation of ileum and pulmonary artery smooth muscle, causes slight urinary bladder smooth muscle contraction at highest tested concentrations. Arcapillin binds to the active site of SARS-CoV-2 M_pro via interactions with Gln139, His163, and His164, exhibits antiviral activity against SARS-CoV-2 and MERS-CoV. Arcapillin can be used for the research of gastrointestinal disorders, COVID-19, and Middle East respiratory syndrome (MERS) .

HY-10419A

AH23848 hemicalcium salt 1 Publications Verification	Prostaglandin Receptor	Cardiovascular Disease
AH23848 hemicalcium salt is an orally active, selective competitive blocker of the thromboxane A₂ receptor, with an IC₅₀ value of 50 nM. AH23848 hemicalcium salt shows no activity against other prostaglandin, serotonin (5-HT) or adenosine diphosphate (ADP) receptors. AH23848 hemicalcium salt can be used in the research of occlusive vascular diseases .

HY-10419

AH23848	Thrombopoietin Receptor	Cardiovascular Disease
AH23848 (compound 6) is a competitive blocker of the thromboxane A₂ receptor and an orally effective agent, with an IC₅₀ value of 50 nM against human targets and a long duration of action.

HY-12378A

BQ-123 TFA	Endothelin Receptor	Cardiovascular Disease
BQ-123 TFA is a potent and selective endothelin A (ETA) receptor antagonist with an IC₅₀ of 7.3 nM and a K_i of 25 nM. BQ-123 TFA inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells and lowers blood pressure in different rat models of hypertension .

HY-121208

Ketanserinol R 46742	5-HT Receptor Drug Metabolite	Neurological Disease
Ketanserinol (R 46742) is a metabolite of Ketanserin (HY-10562). Ketanserinol is a competitive antagonist of the effects of 5-HT (HY-B1473A) in both arteries. The K_B values are 6.5 for large coronary arteries and 6.4 for pulmonary arteries .

HY-130448

8-iso Prostaglandin F1β	Prostaglandin Receptor ROCK	Cardiovascular Disease
8-iso Prostaglandin F1β is an isoprostane, that exhibits vasoconstrictive effect in neonatal porcine pulmonary arteries, pulmonary veins, and mesenteric arteries. 8-iso Prostaglandin F1β targets TXA2 receptor and exhibits the blood vessel contractile efficacy under the influence of tyrosine kinase and Rho kinase .

HY-106861

NIP-121	Potassium Channel	Cardiovascular Disease
NIP-121 is a new type of potassium channel opener. NIP-121 significantly reduces mean pulmonary artery pressure and total pulmonary resistance through vasodilation. NIP-121 can be used for research on pulmonary arterial hypertension .

HY-133594

Sandaracopimaric acid	GABA Receptor	Cardiovascular Disease Inflammation/Immunology
Sandaracopimaric acid is a diterpenoid with anti-inflammatory effect. Sandaracopimaric acid reduces the contraction of phenylephrine-induced pulmonary arteries with an EC₅₀ of 43.93 μM .

HY-A0096A

(Z)-Iloprost (Z)-Ciloprost; (Z)-ZK 36374	Others	Cardiovascular Disease
(Z)-Iloprost ((Z)-Ciloprost; (Z)-ZK 36374) is a vasodilator that prevents heparin-induced platelet activation .

HY-B0813R

Treprostinil diethanolamine (Standard) UT-15C (Standard)	Reference Standards Prostaglandin Receptor	Endocrinology
Geniposide (Standard) is the analytical standard of Geniposide. This product is intended for research and analytical applications. Geniposide is an iridoid glucoside extracted from Gardenia jasminoidesEllis fruits; exhibits a varity of biological activities such as anti-diabetic, antioxidative, antiproliferative and neuroprotective activities.

HY-P1435A

NoxA1ds TFA	NADPH Oxidase	Cardiovascular Disease Cancer
NoxA1ds TFA is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds TFA inhibits NOX1-derived O ^2- production in HT-29 human colon cancer cells. NoxA1ds TFA attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds TFA can be used in the study of hypertension, atherosclerosis and tumors .

HY-118378

ZD6021	Neurokinin Receptor	Neurological Disease Endocrinology
ZD6021 is an orally active Neurokinin 1 Receptor antagonist, with K_i values of 0.12 nM for NK1 and 0.62 nM for NK2. At a concentration of 100 nM, ZD6021 has a pK_B value of 8.9 for human pulmonary artery NK1 receptors, and a pK_B value of 7.3 for human bronchial NK2 receptors. ZD6021 effectively reduces ASMSP-induced plasma protein extravasation in guinea pigs, with an ED₅₀ of 0.5 mg/kg, and also decreases NK2 mediated bronchoconstriction, with an ED₅₀ of 13 mg/kg .

HY-106080A

Furegrelate sodium U-63557A	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-106080

Furegrelate U-63557A free acid	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate is being developed as an antiplatelet agent .

HY-106080AR

Furegrelate sodium (Standard) U-63557A (Standard)	Prostaglandin Receptor Reference Standards	Cardiovascular Disease
Furegrelate (sodium) (Standard) is the analytical standard of Furegrelate (sodium). This product is intended for research and analytical applications. Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-W040167

VPC 23153	LPL Receptor	Cardiovascular Disease
VPC 23153 is a S1P₄ receptor agonist and vasoconstrictor. VPC 23153 activates the S1P₄ receptor, thereby triggering vasoconstriction. VPC 23153 induces pulmonary artery contraction. VPC 23153 can be used in studies related to pulmonary arterial hypertension .

HY-101369R

BW-723C86 (Standard)	5-HT Receptor Reference Standards	Cardiovascular Disease Neurological Disease
BW-723C86 (Standard) is the analytical standard of BW-723C86 (HY-101369). This product is intended for research and analytical applications. BW-723C86 is an orally active and a selective 5-HT2B receptor agonist. BW-723C86 exhibits anxiolytic-like actions. BW-723C86 also causes hyperphagia and reduced grooming in rats. BW-723C86 dilates pulmonary arteries and inhibits liquid meal-induced gastric accommodation .

HY-183644

LNO 9	Lysyl Oxidase	Cardiovascular Disease
LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC₅₀ of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension .

HY-180585

LOXL2/sGC modulator-2	Monoamine Oxidase Guanylate Cyclase PKG Collagen	Cardiovascular Disease
LOXL2/sGC modulator-2 (Compound 9k) is a selective and orally active lysyl oxidase-like 2 (LOXL2) and soluble guanylate cyclase (sGC) dual-target regulator. LOXL2/sGC modulator-2 shows inhibitory activity for LOXL2 with an IC₅₀ of 0.1 μM and can activate sGC. LOXL2/sGC modulator-2 can ameliorate vascular remodeling and reduce pulmonary artery pressure. LOXL2/sGC modulator-2 can downregulate PKG1, PCNA, α-SMA, collagen I and fibronectin levels. LOXL2/sGC modulator-2 can be used for the research of pulmonary arterial hypertension .

HY-107416R

RHC 80267 (Standard) U-57908 (Standard)	DAGL Reference Standards Acyltransferase mAChR COX Phospholipase	Neurological Disease Metabolic Disease
RHC 80267 (Standard) is the analytical standard of RHC 80267 (HY-107416). This product is intended for research and analytical applications. RHC 80267 (U-57908) is a potent and selective inhibitor of diacylglycerol lipase (DAGL) (with IC₅₀ of 4 μM in canine platelets). RHC-80267 inhibits cholinesterase activity with an IC₅₀ of 4 μM, thereby enhancing the relaxation evoked by acetylcholine. RHC 80267 also inhibits COX and the hydrolysis of phosphatidylcholine (PC) .

Cat. No.	Product Name	Target	Research Area